The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Grant(A) | 939 | $22.22 | $21K |
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | Grant(A) | 178K | — | $0 |
| May 13, 2026 | Schneider Paul R | EVP, General Counsel | Grant(A) | 119K | — | $0 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | Grant(A) | 70K | — | $0 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | Grant(A) | 70K | — | $0 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | Grant(A) | 47K | — | $0 |
| Apr 9, 2026 | Schayowitz Adam | See Remarks | Grant(A) | 76K | — | $0 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | Grant(A) | 47K | — | $0 |
| Apr 9, 2026 | Platshon Scott | EVP, Chief Business Officer | Grant(A) | 76K | — | $0 |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | Grant(A) | 178K | — | $0 |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | Grant(A) | 119K | — | $0 |
| Apr 6, 2026 | Stafford Kristin | EVP, Chief Financial Officer | Grant(A) | 50K | — | $0 |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 64K | — | $0 |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell(S) | 30K | $22.67 | $690K |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Grant(A) | 216K | — | $0 |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Grant(A) | 222K | — | $0 |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Grant(A) | 144K | — | $0 |
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 64K | — | $0 |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 18K | — | $0 |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell(S) | 10K | $22.67 | $217K |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Grant(A) | 47K | — | $0 |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Grant(A) | 66K | — | $0 |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Grant(A) | 70K | — | $0 |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 18K | — | $0 |
| Jan 12, 2026 | Mahony Susan | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Mahony Susan | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Campoy Carlos | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Campoy Carlos | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Cesano Alessandra | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Cesano Alessandra | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Landry Robert E | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Landry Robert E | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Neu Kelvin | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Neu Kelvin | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Ciongoli Gregory Austin | Director | Grant(A) | 8K | — | $0 |
| Jan 12, 2026 | Ciongoli Gregory Austin | Director | Grant(A) | 12K | — | $0 |
| Jan 12, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise(M) | 18K | — | $0 |
| Jan 12, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell(S) | 9K | $22.67 | $211K |
| Jan 12, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise(M) | 18K | — | $0 |
| Jan 12, 2026 | Cherry Brian N | Director | Grant(A) | 23K | — | $0 |
| Jan 12, 2026 | Cherry Brian N | Director | Grant(A) | 15K | — | $0 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Option exercise(M) | 18K | — | $0 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Sell(S) | 6K | $22.67 | $139K |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Grant(A) | 47K | — | $0 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Grant(A) | 66K | — | $0 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Grant(A) | 70K | — | $0 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Option exercise(M) | 18K | — | $0 |
| Jan 6, 2026 | Patterson Leone D | EVP, Chief Bus & Fin Officer | Grant(A) | 459 | $10.55 | $5K |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell(S) | 11K | $25.10 | $272K |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell(S) | 9K | $25.10 | $233K |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 17K | — | $0 |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 20K | — | $0 |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 20K | — | $0 |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Option exercise(M) | 17K | — | $0 |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 48K | — | $0 |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell(S) | 32K | $25.10 | $795K |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell(S) | 23K | $25.10 | $569K |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 67K | — | $0 |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 67K | — | $0 |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 48K | — | $0 |
| Jan 5, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise(M) | 20K | — | $0 |
| Jan 5, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell(S) | 11K | $25.10 | $265K |
| Jan 5, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise(M) | 20K | — | $0 |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO, Director | Sell(S) | 48K | $27.02 | $1.3M |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 100K | — | $0 |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO, Director | Option exercise(M) | 100K | — | $0 |
| Aug 12, 2025 | Ciongoli Gregory Austin | Director | Grant(A) | 415K | $12.02 | $5.0M |
| Aug 11, 2025 | Landry Robert E | Director | Grant(A) | 62K | — | $0 |
| Aug 11, 2025 | Ciongoli Gregory Austin | Director | Grant(A) | 62K | — | $0 |
| Jun 26, 2025 | Nodelman Oleg | Director, 10% Owner | Option exercise(X) | 5.1M | — | $0 |
| Jun 26, 2025 | Nodelman Oleg | Director, 10% Owner | Tax withholding(F) | 41 | $12.71 | $521 |
| Jun 26, 2025 | Nodelman Oleg | Director, 10% Owner | Option exercise(X) | 5.1M | — | $0 |
| May 19, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 6K | $11.78 | $70K |
| May 15, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 50K | $11.43 | $566K |
| Apr 17, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 55K | $11.52 | $631K |
| Apr 16, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 74K | $11.16 | $825K |
| Apr 4, 2025 | Nodelman Oleg | Director, 10% Owner | Buy(P) | 196K | $11.17 | $2.2M |
| Apr 3, 2025 | Nodelman Oleg | Director, 10% Owner | Buy(P) | 121K | $11.84 | $1.4M |
| Apr 2, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 74K | $11.85 | $881K |
| Apr 1, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 49K | $11.60 | $564K |
| Mar 31, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 4K | $11.75 | $52K |
| Mar 26, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 44K | $12.24 | $537K |
| Mar 25, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 54K | $12.91 | $691K |
| Mar 24, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 23K | $13.08 | $297K |
| Mar 21, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 31K | $12.78 | $397K |
| Mar 20, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 73K | $12.93 | $950K |
| Mar 19, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 58K | $12.64 | $737K |
| Mar 18, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 114K | $12.65 | $1.4M |
| Mar 17, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 56K | $12.23 | $688K |
| Mar 13, 2025 | Nodelman Oleg | Director, 10% Owner | Buy(P) | 468K | $12.48 | $5.8M |
| Mar 12, 2025 | Nodelman Oleg | Director, 10% Owner | Buy(P) | 293K | $12.25 | $3.6M |
| Mar 11, 2025 | Nodelman Oleg | Director, 10% Owner | Buy(P) | 321K | $11.49 | $3.7M |
| Jan 17, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 20K | $13.87 | $274K |
| Jan 16, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 122K | $13.89 | $1.7M |
| Jan 15, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 39K | $14.01 | $547K |
| Jan 14, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 55K | $13.56 | $739K |
| Jan 13, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 74K | $13.39 | $993K |
| Jan 10, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy(P) | 204K | $13.13 | $2.7M |
| Jan 10, 2025 | Galbraith Kenneth | Chair & CEO, Director | Grant(A) | 288K | — | $0 |
| Jan 10, 2025 | Galbraith Kenneth | Chair & CEO, Director | Grant(A) | 192K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).